Olysio Fact Sheet
Olysio (simeprevir) is an HCV-fighting drug. It must be used with other drugs to treat hepatitis C. In the United States, Olysio is approved for people with hepatitis C genotype 1 who are over 18 years old.
Ending the HIV Epidemic (ETE) in NYS
Ending AIDS as an epidemic is not just the right thing to do for the health of New Yorkers – it’s also cost-effective. We simply can’t afford a status-quo approach to HIV.
Have a Heart, Save My liver!
February 14, 2013 – Today, on the occasion of Valentine's Day, Médecins du Monde and Treatment Action Group (TAG) are launching an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis…
Letter to the EMA: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783)
May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…